# OnCo record paper-bedrosian-asco-sso-germline-testing-breast-jco-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-bedrosian-asco-sso-germline-testing-breast-jco-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-bedrosian-asco-sso-germline-testing-breast-jco-2024" ;
  schema:name "Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline"@en ;
  schema:description "The 2024 American guideline says every woman diagnosed with breast cancer at 65 or under should be offered BRCA1/2 testing, as should anyone who might be treated with a PARP inhibitor, whatever her family history."@en ;
  schema:url <https://onco.cc/key-papers/paper-bedrosian-asco-sso-germline-testing-breast-jco-2024/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.23.02225>, <https://pubmed.ncbi.nlm.nih.gov/38175972/>, <https://ascopubs.org/topics/asco-guidelines/breast-cancer> ;
  schema:sameAs <https://doi.org/10.1200/JCO.23.02225> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Bedrosian I, Somerfield MR, Achatz MI, et al." ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/breast-cancer/> ;
  onco:technologies <https://onco.cc/technologies/germline-testing/> ;
  onco:targets <https://onco.cc/targets/brca/> ;
  onco:drugs <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/talazoparib/> ;
  onco:terms <https://onco.cc/terms/gbrca-mutation/>, <https://onco.cc/terms/vus/>, <https://onco.cc/terms/germline-vs-somatic/> ;
  onco:people <https://onco.cc/people/giuseppe-curigliano/> ;
  onco:journals <https://onco.cc/journals/jco/> .